NEW YORK (GenomeWeb News) – Fluidigm said that it may become entitled to certain tax incentives for its business in Singapore, under a proposal from the Singapore Economic Development Board. The South San Francisco-based microfluidics and sample preparation technologies firm said that the tax incentives depend on the size and scope of its business in Singapore and its aggregate investments there. Fluidigm noted that affiliated entities of the Singapore EDB, BioMedical Sciences Investment Fund and Singapore Bio-Innovations, hold around 9 percent of the firm's capital stock.
Artemis Health has changed its name to Verinata Health. The San Carlos, Calif.-based firm is developing a non-invasive pre-natal diagnostic test to detect fetal chromosomal abnormalities, such as the one associated with Down syndrome. This week, Verinata published results of an initial validation study of a sequencing-based prenatal test to identify multiple fetal chromosomal abnormalities, including trisomy 21 and trisomy 18, in the journal Clinical Chemistry.
Pacific Biomarkers said this week that it has been awarded nine contracts by one unnamed sponsor to conduct biomarker services. The contracts have a total value of around $920,000, and the work will be conducted from 2011 to 2014.